
|Articles|June 1, 2003
- Psychiatric Times Vol 20 No 6
- Volume 20
- Issue 6
After the Famous Poet
Poetry of the Times
Advertisement
After the Famous Poet
recites a poem
that ends with "a purple stain,"
she recalls how she went to war
with another famous poet
about whether it is proper
to end a poem with a color.
And I envy the famous poet
for living in a world
where battles over colorful words
can feel like life and death.
For years ago I chose a world
where colorful words
like "green meconium stain"
or "peau d'orange"
describe deformity beyond metaphor,
a war where flesh is cut and colored
to let us read the body's text,
our precise choice of words
as brilliant and final
as the last line of any poem.
Articles in this issue
over 23 years ago
Confidentiality Under Fireover 23 years ago
Stigma Continues in Hollywoodover 23 years ago
The Art of the Unconsciousover 23 years ago
Psychiatrists Strive to Assure Patients' Safetyover 23 years ago
Conference Probes Pathology of Self-Awarenessover 23 years ago
Music Therapy With Emotionally Disturbed Childrenover 23 years ago
The Assessment of Danger in Everyday Practiceover 23 years ago
The Other Side of the Storyover 23 years ago
Using Creativity to Explore in PsychotherapyAdvertisement
Related to this article

Rethink “treatment-resistant depression” by adopting difficult-to-treat depression, verifying adequate trials, and stratifying drivers like trauma and inflammation to improve outcomes.

Once-monthly subcutaneous olanzapine LAI requires no loading doses, oral supplementation, or post-injection monitoring, based on phase 3 SOLARIS data.

Neurosterix advances NTX-253, an oral M4 PAM, into phase 2 for schizophrenia after phase 1 shows promising safety and pharmacokinetics.

Andrew A. Nierenberg, MD, explains how a learning health network helps clinicians measure outcomes and redesign bipolar disorder care together with patients.

Routine symptom measures sharpen psychiatric diagnosis, speed remission, flag relapse risk, and turn EHR data into a learning system for better care.

Seaport begins phase 2a trial of GlyphAgo for generalized anxiety disorder with sleep disturbance, testing liver-sparing agomelatine dosing and tracking sleep, anxiety outcomes.

FDA clears Motivista, a prescription smartphone digital therapeutic, to reduce negative symptoms of schizophrenia—supported by phase 3 results and strong patient engagement.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Olanzapine LAI (Weltruza) Receives FDA Approval for Schizophrenia
2
Moving Away From Treatment-Resistant Depression and Toward Difficult-to-Treat Depression
3
Blood-Based Biomarkers for Alzheimer Disease: Accuracy, Limits, and Confounders
4
FDA Grants Clearance to Motivista, the First Authorized Treatment for Negative Symptoms of Schizophrenia
5

